NASDAQ: CRDFCardiff Oncology Inc Stock
$4.18+0.01 (+0.24%)
Updated Apr 24, 2024
CRDF Price
$4.18
Fair Value Price
$0.12
Market Cap
$186.75M
52 Week Low
$0.94
52 Week High
$6.42
P/E
-4.49x
P/B
2.68x
P/S
135.5x
PEG
N/A
Dividend Yield
N/A
Revenue
$488.00k
Earnings
-$41.44M
Gross Margin
100%
Operating Margin
-8,492.01%
Profit Margin
-8,496.9%
Debt to Equity
0.17
Operating Cash Flow
-$31M
Beta
1.18
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CRDF Overview
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CRDF scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRDF ($4.18) is overvalued by 3,467.3% relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRDF ($4.18) is not significantly undervalued (3,467.3%) relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRDF is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRDF due diligence checks available for Premium users.
Be the first to know about important CRDF news, forecast changes, insider trades & much more!
CRDF News
Valuation
CRDF fair value
Fair Value of CRDF stock based on Discounted Cash Flow (DCF)
Price
$4.18
Fair Value
$0.12
Overvalued by
3,467.30%
CRDF ($4.18) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRDF ($4.18) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRDF is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CRDF price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.49x
Industry
15.69x
Market
41.27x
CRDF price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.68x
Industry
5.86x
CRDF is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRDF's financial health
Profit margin
Revenue
$156.0k
Net Income
-$9.3M
Profit Margin
-5,989.1%
CRDF's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CRDF's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$81.6M
Liabilities
$11.9M
Debt to equity
0.17
CRDF's short-term assets ($77.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRDF's short-term assets ($77.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRDF's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRDF's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.1M
Investing
$13.6M
Financing
$0.0
CRDF's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRDF vs Biotech Stocks
Cardiff Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.